Found: 5
Select item for more details and to access through your institution.
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
- Published in:
- In Vivo, 2022, v. 36, n. 3, p. 1302, doi. 10.21873/invivo.12831
- By:
- Publication type:
- Article
Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 6, p. e335, doi. 10.1111/bjh.16903
- By:
- Publication type:
- Article
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 9, p. 2279, doi. 10.1007/s00277-021-04421-2
- By:
- Publication type:
- Article
Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy.
- Published in:
- European Journal of Haematology, 2002, v. 68, n. 5, p. 289, doi. 10.1034/j.1600-0609.2002.01721.x
- By:
- Publication type:
- Article
Identification of Very Low‐Risk Subgroups of Patients with Primary Mediastinal Large B‐Cell Lymphoma Treated with R‐CHOP.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 597, doi. 10.1002/onco.13789
- By:
- Publication type:
- Article